2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
18
Neoplasm Metastasis
2
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
Pain
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Biochemical Recurrent Prostate Cancer
1
Interventions
enzalutamide
5
abiraterone
2
Radiotherapy
2
Metastasectomy
2
Abiraterone Acetate
2
testosterone enanthate
1
radium Ra 223 dichloride
1
pembrolizumab
1
disitamab vedotin
1
dactolisib
1
VT-464
1
Radium-223
1
Radiosurgery
1
Prednisone
1
NVP-BKM120
1
Ketoconazole
1
Injections
1
Hydrocortisone
1
Flutamide
1
Cyclophosphamide
1
Crizotinib
1
Control Groups
1
Carboplatin
1
Calcitriol
1
Blood Specimen Collection
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Castration-resistant Prostate Cancer
×
Radium-223
×
Clear all
NCT03305224
2021-09-09
CORE-OCU
Osaka City University
Phase 2
Unknown
10 enrolled